Is Aadi Bioscience, Inc. overvalued or undervalued?

As of 8 May 2025, Aadi Bioscience, Inc. has moved from a risky to an attractive valuation grade. The company is currently considered undervalued, with a P/E ratio of 3, a Price to Book Value of 0.40, and an impressive ROCE of 648.45%. In comparison, its peer Theseus Pharmaceuticals, Inc. has a P/E ratio of -3.17, while Vaxart, Inc. is rated risky with a P/E of -2.34, highlighting Aadi's relative strength in valuation metrics.
Despite recent stock performance showing a year-to-date decline of 38.19% compared to a 2.44% gain in the S&P 500, the company's low PEG ratio of 0.02 suggests significant growth potential. Overall, Aadi Bioscience appears to be an attractive investment opportunity within its sector, particularly given its favorable ratios compared to peers.